Skip to main content
Top
Published in: International Journal of Clinical Oncology 2/2015

01-04-2015 | Special Article

Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer

Authors: Yasuhiko Ebina, Nobuo Yaegashi, Hidetaka Katabuchi, Satoru Nagase, Yasuhiro Udagawa, Toru Hachisuga, Tsuyoshi Saito, Mikio Mikami, Yoichi Aoki, Hiroyuki Yoshikawa

Published in: International Journal of Clinical Oncology | Issue 2/2015

Login to get access

Abstract

The second edition of the Japan Society of Gynecologic Oncology guidelines for the treatment of uterine cervical cancer was published in 2011. The guidelines comprise eight chapters and five algorithms. They were prepared by consensus among the members of the Japan Society of Gynecologic Oncology Guidelines Formulation Committee and Evaluation Committee and are based on a careful review of the evidence obtained from the literature, health insurance system, and actual clinical settings in Japan. The highlights of the 2011 revision are (1) the recommended grades have been changed to five stages—A, B, C1, C2, and D; (2) the revisions are consistent with the new International Federation of Gynecology and Obstetrics staging system; (3) the roles are shared between the ‘Japanese classification of cervical cancer’ and the new guidelines; (4) clinical questions related to adenocarcinoma have been revised; and (5) a clinical question regarding cervical cancer in pregnant patients has been added. Each chapter includes a clinical question, recommendations, background, objectives, explanations, and references. Each recommendation is accompanied by a classification of recommendation categories. The objective of these guidelines is to update the standard treatment strategies for cervical cancer, thus eliminating unnecessary and insufficient treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gynecologic cancer committee (2012) Gynecologic cancer committee report in 2011. Acta Obstetrica et Gynaecologica Japonica 64:2340–2388 Gynecologic cancer committee (2012) Gynecologic cancer committee report in 2011. Acta Obstetrica et Gynaecologica Japonica 64:2340–2388
3.
go back to reference Nagase S, Inoue Y, Umesaki N et al (2010) Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition. Int J Clin Oncol 15:117–124CrossRefPubMed Nagase S, Inoue Y, Umesaki N et al (2010) Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition. Int J Clin Oncol 15:117–124CrossRefPubMed
4.
go back to reference Ariyoshi H (2002) Guideline for correct use of antineoplastic agents (draft). General theory. Gan To Kagaku Ryoho 29:970–977 Ariyoshi H (2002) Guideline for correct use of antineoplastic agents (draft). General theory. Gan To Kagaku Ryoho 29:970–977
5.
go back to reference Ochiai K, Okamoto A, Katsumata N (2002) Guidelines for proper use of antineoplastic agents. Gynecologic cancer. Gan To Kagaku Ryoho 29:1047–1054PubMed Ochiai K, Okamoto A, Katsumata N (2002) Guidelines for proper use of antineoplastic agents. Gynecologic cancer. Gan To Kagaku Ryoho 29:1047–1054PubMed
6.
go back to reference Fukui T, Yoshida M, Yamaguchi N (2007) Minds Guidance of practice guidelines 2007. Igakushoin, Tokyo Fukui T, Yoshida M, Yamaguchi N (2007) Minds Guidance of practice guidelines 2007. Igakushoin, Tokyo
Metadata
Title
Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer
Authors
Yasuhiko Ebina
Nobuo Yaegashi
Hidetaka Katabuchi
Satoru Nagase
Yasuhiro Udagawa
Toru Hachisuga
Tsuyoshi Saito
Mikio Mikami
Yoichi Aoki
Hiroyuki Yoshikawa
Publication date
01-04-2015
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0806-7

Other articles of this Issue 2/2015

International Journal of Clinical Oncology 2/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine